首页> 外文期刊>World Journal of Gastroenterology >Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi.
【24h】

Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi.

机译:胆管肿瘤血栓合并肝细胞癌的外科治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To study the surgical treatment effect and outcome of hepatocellular carcinoma (HCC) with bile duct tumor thrombi (BDTT). METHODS: Fifty-three consecutive HCC patients with BDTT admitted in our department from July 1984 to December 2002 were reviewed retrospectively. The clinical data, diagnostic methods, surgical procedures and outcome of these patients were collected and analyzed. RESULTS: One patient rejected surgical treatment, 6 cases underwent percutaneous transhepatic cholangial drainage (PTCD) for unresectable primary disease, and the other 46 cases underwent surgical operation. The postoperative mortality was 17.6%, and the morbidity was 32.6%. Serum total bilirubin levels of these patients with obstructive jaundice decreased gradually after surgery. The survival time of six cases who underwent PTCD ranged from 2 to 7 mo (median survival of 3.7 mo). The survival time of the patients who received surgery was as follows: 2 mo for one patient who underwent laparotomy, 5-46 mo (median survival of 23.5 mo, which was the longest survival in comparison with patients who underwent other procedures, P = 0.0024) for 17 cases who underwent hepatectomy, 5-17 mo (median survival of 10.0 mo) for 5 cases who underwent HACE, 3-9 mo (median survival of 6.1 mo) for 11 cases who underwent simple thrombectomy and biliary drainage, and 3-8 mo (median survival of 4.3 mo) for four cases who underwent simple biliary drainage. CONCLUSION: Jaundice caused by BDTT in HCC patients is not a contraindication for surgery. Only curative resection can result in long-term survival. Early diagnosis and surgical treatment are the key points to prolong the survival of patients.
机译:目的:研究胆管肿瘤血栓(BDTT)对肝细胞癌(HCC)的手术治疗效果和疗效。方法:回顾性分析我科1984年7月至2002年12月收治的53例BDTC患者。收集并分析这些患者的临床数据,诊断方法,手术程序和结果。结果:1例患者拒绝手术治疗,6例因无法切除的原发性疾病接受了经皮肝穿刺胆管引流术(PTCD),其他46例接受了手术治疗。术后死亡率为17.6%,发病率为32.6%。这些梗阻性黄疸患者的血清总胆红素水平在手术后逐渐下降。接受PTCD的6例患者的生存时间为2到7个月(中位生存期为3.7个月)。接受手术的患者的生存时间如下:一名接受剖腹手术的患者为2个月,为5-46个月(中位生存期为23.5个月,与接受其他手术的患者相比,最长的生存期为P = 0.0024 )接受肝切除术的17例患者,接受HACE治疗的5例患者的5-17个月(中位生存期为10.0个月),接受简单血栓切除和胆道引流的11例患者中3个月接受了3-9个月(中位生存期为6.1个月),3四例行单纯胆汁引流的患者为-8个月(中位生存期为4.3个月)。结论:BDTT引起的HCC患者黄疸并非手术禁忌症。只有根治性切除才能导致长期生存。早期诊断和手术治疗是延长患者生存期的关键。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号